Endocrine Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Clinical Trials
• Forums

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Apatinib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Condition:   Breast Cancer Metastatic Cancer Interventions:   Drug: Fluzoparib;   Drug: Dalpiciclib;   Drug: Fulvestrant/AI Sponsor:   Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2023 Category: Research Source Type: clinical trials

Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients
Condition:   Female Breast Cancer Interventions:   Drug: Hormonal Antineoplastics;   Drug: Chemotherapy drug Sponsor:   Sohag University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials